<DOC>
	<DOC>NCT01479465</DOC>
	<brief_summary>This randomized study compares the efficacy of simtuzumab (GS-6624) versus placebo in combination with FOLFIRI (fluorouracil, leucovorin, and irinotecan) chemotherapy regimen in participants with metastatic KRAS mutant colorectal cancer.</brief_summary>
	<brief_title>Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Metastatic Colorectal Carcinoma with KRAS mutation. Received first line therapy and discontinued part or all of first line therapy. Estimated life expectancy &gt; 3 months. Stage IV disease. Eastern Cooperative Oncology Group (ECOG) 02. Adequate hepatic and hematologic function No major operations within 4 weeks prior to treatment start. More than 1 prior chemotherapy regimen for stage 4 colorectal cancer. Experimental medical treatment within 30 days prior to study entry. Known or suspected cerebral metastases. History or presence of any form of cancer, other that colorectal cancer, within the 3 years prior to enrollment. Known dihydropyrimidine dehydrogenasedeficiency (special screening not required). Subjects with angina pectoris, poorly controlled ventricular arrhythmias (does not include asymptomatic, occasional premature ventricular contractions), history of clinically significant coronary heart disease or cardiomyopathy, or ECG abnormalities consistent with ischemia. Uncontrolled hypertension (seated systolic blood pressure &gt; 180 mmHg or diastolic blood pressure &gt; 110 mmHg) at Screening. Clinically active liver disease, including active hepatitis (any etiology) or cirrhosis. Antitumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) within 21 days prior to randomization Prior irinotecan therapy for metastatic disease is not permitted. Systemic fungal, bacterial, viral, or other infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>GSI</keyword>
	<keyword>Gilead</keyword>
	<keyword>Gilead Sciences</keyword>
	<keyword>GS-6624</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>KRAS</keyword>
	<keyword>Oncology</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>